Daratumumab (DARA) is a CD38-targeting human IgG1 mAb that has demonstrated clinical efficacy in the treatment of multiple myeloma (MM), both as a single agent and in combination regimens.20 21 DARA exerts its antitumor effects via multiple mechanisms of action, including potent NK cell-mediated ADCC,5 making DARA an attractive agent to combine with adoptive NK cell infusions. This evidence concerns the gene CD38 and Miyoshi myopathy.